{"id":"https://openalex.org/W2469375526","doi":null,"title":"Does neuroleptic blocking of dopamine receptors continue after chronic treatment?","display_name":"Does neuroleptic blocking of dopamine receptors continue after chronic treatment?","publication_year":1980,"publication_date":"1980-01-01","ids":{"openalex":"https://openalex.org/W2469375526","mag":"2469375526","pmid":"https://pubmed.ncbi.nlm.nih.gov/6108567"},"language":"en","primary_location":{"id":"pmid:6108567","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/6108567","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Progress in biochemical pharmacology","raw_type":"Comparative Study"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112165975","display_name":"Robert H. Belmaker","orcid":"https://orcid.org/0000-0001-9734-1829","observed_orcids":["https://orcid.org/0000-0001-9734-1829"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R H Belmaker","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045240458","display_name":"Haim H. Dasberg","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H Dasberg","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5012156936","display_name":"Richard P. Ebstein","orcid":"https://orcid.org/0000-0002-3626-541X","observed_orcids":["https://orcid.org/0000-0002-3626-541X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R P Ebstein","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.39583333,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"16","issue":null,"first_page":"109","last_page":"18"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.8823000192642212,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.8823000192642212,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.1096000000834465,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.004100000020116568,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dopamine-receptor-blockade","display_name":"dopamine receptor blockade","score":0.8289999961853027},{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.6200000047683716},{"id":"https://openalex.org/keywords/haloperidol","display_name":"haloperidol","score":0.9350000023841858},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.7059999704360962},{"id":"https://openalex.org/keywords/striatal-dopamine-receptors","display_name":"striatal dopamine receptors","score":0.6899999976158142},{"id":"https://openalex.org/keywords/spiperone-binding","display_name":"spiperone binding","score":0.7580000162124634},{"id":"https://openalex.org/keywords/receptor-binding-affinity","display_name":"receptor binding affinity","score":0.9150000214576721},{"id":"https://openalex.org/keywords/receptor-density","display_name":"receptor density","score":0.7590000033378601},{"id":"https://openalex.org/keywords/camp","display_name":"cyclic AMP","score":0.6909999847412109},{"id":"https://openalex.org/keywords/chronic-drug-administration","display_name":"chronic drug administration","score":0.6169999837875366},{"id":"https://openalex.org/keywords/receptor-desensitization","display_name":"receptor desensitization","score":0.6119999885559082}],"concepts":[{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.6984841227531433},{"id":"https://openalex.org/C2780948584","wikidata":"https://www.wikidata.org/wiki/Q251347","display_name":"Haloperidol","level":3,"score":0.6925065517425537},{"id":"https://openalex.org/C120069818","wikidata":"https://www.wikidata.org/wiki/Q415496","display_name":"Dopamine receptor","level":3,"score":0.6381885409355164},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5952914953231812},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5866643786430359},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.5761277079582214},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.43547219038009644},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.433596134185791},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.40494492650032043},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.39115244150161743},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.11302879452705383}],"mesh":[{"descriptor_ui":"D000242","descriptor_name":"Cyclic AMP","qualifier_ui":"Q000134","qualifier_name":"cerebrospinal fluid","is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003342","descriptor_name":"Corpus Striatum","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006152","descriptor_name":"Cyclic GMP","qualifier_ui":"Q000134","qualifier_name":"cerebrospinal fluid","is_major_topic":false},{"descriptor_ui":"D006220","descriptor_name":"Haloperidol","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011954","descriptor_name":"Receptors, Dopamine","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D011954","descriptor_name":"Receptors, Dopamine","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:6108567","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/6108567","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Progress in biochemical pharmacology","raw_type":"Comparative Study"},{"id":"mag:2469375526","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/6108567","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9476000070571899,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2008253670","https://openalex.org/W2036740754","https://openalex.org/W1975216040","https://openalex.org/W2091793118","https://openalex.org/W1980046226","https://openalex.org/W1985663765","https://openalex.org/W2022707140","https://openalex.org/W2075667047","https://openalex.org/W2418270424","https://openalex.org/W2026077845"],"abstract_inverted_index":{"Neuroleptic":[0],"treatment":[1,114],"of":[2,14,17,41,102,112,128],"schizophrenia":[3],"reduces":[4],"CSF":[5,121],"cyclic":[6,122],"AMP":[7,123],"in":[8,88],"clinical":[9],"responders":[10],"after":[11,38,45,69,74,109,124],"a":[12,81,125],"mean":[13],"8":[15],"weeks":[16,40,71,111],"treatment.":[18,130],"This":[19],"is":[20,67,115],"consistent":[21,116],"with":[22,117],"continued":[23],"effective":[24],"dopamine":[25,104],"receptor":[26,63,97],"blockade":[27],"by":[28,57],"these":[29],"drugs.":[30],"Rat":[31],"striatal":[32,62],"3H-spiroperidol":[33,66,108],"binding":[34,105],"sites":[35,106],"increase":[36],"more":[37],"10":[39,70,110],"haloperidol":[42],"therapy":[43],"than":[44],"3":[46,58,75],"weeks,":[47],"suggesting":[48],"that":[49,84],"physiological":[50],"equilibrium":[51],"has":[52],"not":[53,73],"yet":[54],"been":[55],"reached":[56],"weeks.":[59,76],"The":[60,77,99],"rat":[61,103],"affinity":[64,79,101],"for":[65,107],"decreased":[68,78,100],"but":[72],"represents":[80],"new":[82],"phenomenon":[83],"may":[85],"be":[86],"important":[87],"explaining":[89],"long-term":[90],"continuing":[91],"neuroleptic":[92,113,129],"effectiveness":[93],"despite":[94],"the":[95,118],"increased":[96],"number.":[98],"reduced":[119],"human":[120],"similar":[126],"period":[127]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-07-22T00:00:00"}